<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82203">
  <stage>Registered</stage>
  <submitdate>9/08/2007</submitdate>
  <approvaldate>29/08/2007</approvaldate>
  <actrnumber>ACTRN12607000439448</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of a 96hr duration local anaesthesia (l-bupivacaine) infusion using PainBuster device at the incision site compared with saline controls  for post-operative pain management against  a background of narcotic analgesia, following open or laparoscopic abdominal surgery.</studytitle>
    <scientifictitle>Colorectal surgical patients treated with Chirocaine infusion versus saline at surgical site, and demands/usage of PCA narcotic analgesic and VAS score.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post-operative pain management</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The aim is to test whether continuous local anaesthetic infusion (0.5% l-bupivacaine at 5ml/h for 0-48hr and 2ml/h for 48-96h post-op) using a commercial infiltration device can minimise, or eliminate, the need for narcotic analgesia following abdominal open or laparoscopic surgery. The potential benefits to the patient include earlier mobilisation, minimisation or averting the side-effects from narcotics (a particular issue in elderly patients following abdominal surgery), and shorter length-of-stay.</interventions>
    <comparator>saline placebo infusion, double-blind</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain management measured by (a) reduction in demands and usage of narcotic available using patient-controlled analgesic (PCA) device, and (b) visual analogue pain scores in patients on local anaesthetic infusion compared with saline/placebo controls</outcome>
      <timepoint>pain scores and PCA usage recorded 12 hourly for 96 hours post-op</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>patient satisfaction, mobilisation, return normal bowel function, would infection, length of hospital stay, adverse effects from local anaesthetic, unbound l-bupivacaine concentrations throughout infusion period</outcome>
      <timepoint>wound sterility, drug conc, pain scores determined 12hrly
Satisfaction at discharge and followup</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Able to give informed consent
ASA Score &lt;4 (ie., level 1, 2 or 3)
Normal to mildly elevated biochemical indices of renal and/or hepatic function
Mental status of the patient should be considered and included only if in the opinion of the surgeon and other attended medical staff, that the patient is capable of giving informed consent and would be capable of complying with the reasonable instructions to allow the study to progress
Smokers are admissible, and other drugs/medicines normally taken, other than those specified below</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy. 
ASA Score &gt;4 (ie., level 4, 5)
Moderate to severely elevated indices of renal and/or hepatic function, and patients with dementia
Taking drugs known to influence l-bupivacaine kinetics (CYP1A2 or CYP3A inhibitor/inducers; fluvoxamine, quinoline antibacterials, conazole antifungals)
Taking drugs that may affect pain perception [narcotics (including codeine containing preparations), tricyclic antidepressants, chronic pain killers, anti-epileptic drugs also used in pain therapy)
Patients receiving epidural anaesthesia
Known allergy to l-bupivacaine or fentanyl</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>81</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>5000 numbers</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Queen Elizabeth Hospital</primarysponsorname>
    <primarysponsoraddress>28 Woodville Rd
Woodville SA 5011</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Raymond Morris</fundingname>
      <fundingaddress>Clinical Pharmacology
The Queen Eluizabeth Hospital
Woodville SA 5011</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Surgical Synergies</fundingname>
      <fundingaddress>PO Box 2121
Hilton SA 5033</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Adelaide</sponsorname>
      <sponsoraddress>North Tce
Adelaide SA 5000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Mr Peter Hewett</othercollaboratorname>
      <othercollaboratoraddress>Dept of Surgery
University of Adelaide
TQEH
Woodville SA 5011</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics of Human Research Committee</ethicname>
      <ethicaddress>The Queen Elizabeth Hospital
28 Woodville Rd
Woodville SA 5011</ethicaddress>
      <ethicapprovaldate>1/12/2006</ethicapprovaldate>
      <hrec>2008006</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Raymond Morris</name>
      <address>Clinical Pharmacology
TQEH
Woodville Rd
Woodville SA 5011</address>
      <phone>61882226753</phone>
      <fax>61882226033</fax>
      <email>ray.morris@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Raymond Morris</name>
      <address>Clinical Pharmacology
TQEH
Woodville Rd
Woodville SA 5011</address>
      <phone>61882226753</phone>
      <fax>61882226033</fax>
      <email>ray.morris@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Raymond Morris</name>
      <address>Clinical Pharmacology
TQEH
Woodville Rd
Woodville SA 5011</address>
      <phone>61882226753</phone>
      <fax>61882226033</fax>
      <email>ray.morris@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>